U.S. Markets close in 34 mins

Electromedical Technologies, Inc. (EMED)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.04000.0000 (0.00%)
As of 2:27PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0400
Open1.0400
BidN/A x N/A
AskN/A x N/A
Day's Range0.9020 - 1.0500
52 Week Range0.9020 - 1.0500
Volume17,957
Avg. VolumeN/A
Market Cap29.963M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Electromedical Technologies Produces $4.2 Million in Device Inventory to Meet Demand
    GlobeNewswire

    Electromedical Technologies Produces $4.2 Million in Device Inventory to Meet Demand

    \- Company completes production of 1,200 FDA-cleared WellnessPro\+ devices \- Inventory build completed ahead of on-boarding new medical practitioners and distributors\- Demand driven by pain sufferers desiring non-invasive alternatives SCOTTSDALE, Ariz., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared WellnessPro+ device, representing approximately $4.2 million of inventory to meet demand.The Company began production in September and has fully paid for and completed its first phase of inventory buildup in order to meet rising demand as we transition into 2021. We want to make sure that we do not run out of inventory which occurred in the first quarter of this year.Matthew Wolfson, Founder and CEO of EMED, commented, “Every day more doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. The reason for the increase in demand is that more and more people are realizing that there are other powerful treatment options such as bioelectronics, that does not include injections, invasive procedures or opioids that have the possibility of harmful side effects such as addiction and death.”Commenting further, Mr. Wolfson said, “This inventory increase fits perfectly with our strategic plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.” (https://electromedtech.com/register/)Finally commenting, Mr. Wolfson said, “In the world we live in today, people cannot afford the risks associated with opioid-based drugs, but they need results. Word of mouth has been a very valuable marketing tool because our device delivers a powerful solution to chronic pain without any dangerous or harmful side effects. The Wellness Pro produces real results so people can live pain free and get their lives back!”About Electromedical TechnologiesHeadquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies.For more information, visit www.electromedtech.com.Safe Harbor StatementThis release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.Corporate Contact:Electromedical Technologies, Inc. Matthew Wolfson Tel: 1.888.880.7888 email: ceo@electromedtech.com https://electromedtech.com

  • ACCESSWIRE

    Goldman Small Cap Research Issues New Research Report on Electromedical Technologies, Inc.

    BALTIMORE, MD / ACCESSWIRE / November 18, 2020 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Electromedical Technologies, Inc.

  • Electromedical Technologies, Inc. and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program in “Bioelectronics Therapist and Master Device Technician” to Expand Product Awareness and on Boarding of NEW Device Representatives and Brand Ambassadors
    GlobeNewswire

    Electromedical Technologies, Inc. and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program in “Bioelectronics Therapist and Master Device Technician” to Expand Product Awareness and on Boarding of NEW Device Representatives and Brand Ambassadors

    SCOTTSDALE, Ariz., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro®, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce a collaboration with Energetic Wellness School of Naturopathy to develop a new distribution platform and certification training program to onboard new medical device representatives and improve training for current Wellness Pro ambassadors. Dr. Michele Menzel, ND, D.psc, commented: “We are excited to work with Electromedical Technologies to develop and establish a curriculum/certification program that will include bioelectronics applications such as frequencies used, treatment protocols and treatment techniques, as well as books and materials for students and distributors.Doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. We will make this course available to our students, alumni distributors or anyone interested in the future of medicine to have an opportunity to take our course.”Matthew Wolfson, CEO of Electromedical Technologies, commented, “This program fits perfectly with our plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.” (https://electromedtech.com/register/)The new Master Device Rep program will provide our current device representatives with added bonuses and give interested people who wish to join our team an incredible business opportunity as well. This certification program and curriculum are pending approval.Energetic Wellness School of Naturopathy is located in Edmond, OK https://energeticwellnessok.com/. Its Alumni, health providers, their patients and clients will have access to training and certification in the area of bioelectronics and specifically will have access and training using the Wellness Pro® Plus device and future product line.Dr. Lee Woolley, DNM, GNM, MBnC, commented: “The Wellness Pro® Plus device has a proven track-record with over 10 years of positive results. We have tested and   researched various devices on the market and have not seen any device produce such powerful and long-term pain-relieving effects. That is why we chose to work with Electromedical to provide our students and new healthcare providers access and training on one of the best devices on the market today – The Wellness Pro® Plus.We cannot wait for the company to release its new wearable Wellness Pro® POD next year. This will be a game changer for practitioners and patients dealing with chronic pain, because it gives that ability for the Doctors to provide their patients with safer choices and send the patient home with a POD rather than an bottle of Opioids.Since provider education is imperative in the effective usage of non-invasive, non-toxic bio-electronic wellness methodologies, training assists providers in understanding the foundation, application, research and various methods in effective pain care and management at home and in the office.  It is a great tool for future doctors to be able to run various programs for their patients at their home or office.”Finally, Mr. Wolfson commented, “It was very important to collaborate with such a great institution as the Energetic Wellness School of Naturopathy so that more practitioners and distributors may gain comprehensive knowledge of Bioelectronics, and modern effective medical devices and technologies that produce natural pain relief and overall wellness. Doctors and students will have access to the Wellness Pro® Plus devices, which will give them hands on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain. Bioelectronics will Electrify medicine in the next 5 years and will be the norm in treatments of not only Chronic pain but will also one day open doors to other treatments that will improve human well-being without addictive and harmful side effects. Electromedical (EMED) is part of the wave of the future."About Electromedical Technologies:Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is an FDA cleared  commercial stage bioelectronic medical device manufacturing and distribution company initially focused on the treatment of various chronic, acute, intractable and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.For more information, visit https://electromedtech.comOur animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare.  The United States Food and Drug Administration has not reviewed or approved our animal research studies.Safe Harbor Statement:This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.Electromedical Technologies, Inc. Matthew Wolfson Tel: 1.888.880.7888 email: ceo@electromedtech.com www.electromedtech.com